Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced a significant milestone in its ongoing Phase 2 clinical study, ACTIVATE (clinicaltrials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback